Our Meetings

Annual General Meeting

November 4th, 2020 11:00-12:30 EST

Please save the above date for the Virtual Annual General Meeting. A full programme will be posted nearer the time. At the Annual General Meeting, members will be asked to approve Amended and Restated Bylaws of the SCTC.   

 A two-thirds vote of the Members is required to approve the updated Bylaws. In order to ensure a sufficient number of votes, the President of the SCTC will vote on your behalf as your Proxy if you do not attend the Meeting. 

If you wish to appoint a different individual to vote on your behalf as your Proxy, you may complete the attached Proxy form and return it to sctcinc01@gmail.com no later than November 3, 2020.   Note that if you return a completed Proxy form but you do attend the Meeting, your Proxy form will be destroyed when you sign in at the Meeting so that you can vote in person.

6th Systemic Sclerosis World Congress SCTC-WSF-FWSF Travel Awards

Awardees of SCTC-WSF-FWSF Travel Awards World Congress 2020

The SCTC, the World Scleroderma Foundation (WSF) and the Friends of the World Scleroderma Foundation (FWSF) are pleased to announce that the following were successful in their application for a Travel Award to attend the 6th Systemic Sclerosis World Congress in Prague:

  • Kimberly Showalter, MD - Hospital for Special Surgery, New York, USA
    "CD34 and alpha-smooth muscle actin distinguish scleroderma gene expression subsets using a machine learning approach"
  • Sabrina Hoa, MD, MSc, FRCPC - Centre Hospitalier de l'Université de Montréal, Canada
    "Prevention of interstitial lung disease with immunosuppressive therapy in systemic sclerosis"
  • Antonia Valenzuela, MDPontificia Universidad Católica de Chile
    "Change in calcinosis over 1 year using the SCTC Radiologic Scoring System for Calcinosis of the hands in patients with Systemic Sclerosis"
  • Rebecca Ross, MD - University of Leeds, UK
    "Biosamples from at risk SSc patients show classic pathological signs of Scleroderma: opportunity for a diagnosis of pre-clinical SSc"
  • Sandra Maximiano, MD - Federal University of São Paulo, Brazil
    "Microparticles in systemic sclerosis: a promising biomarker of microvascular damage?"
  • Fan Xiubo, MD - Singapore General Hospital, Singapore
    "CXCL5 ameliorates systemic sclerosis via suppressing helper T cell-mediated immune response"
  • Raluca Dumitru, MDLeeds Institute of Rheumatic and Musculoskeletal Medicine, UK
    "Serum cardiac biomarkers and cardiac MRI diffuse fibrosis may predict the development of cardiovascular events in systemic sclerosis patients"
  • Boyang Zheng, MD - McGill University, Montreal, Canada
    "Systemic sclerosis auto-antibody profiles predict interstitial lung disease onset but not progression"
  • Janine Schniering, MD - University Hospital Zurich, Switzerland
    "Computed tomography-based radiomics features for detection and staging of interstitial lung disease in Systemic Sclerosis - transferability from experimental to human lung fibrosis"
  • Melody Pei-Shien Chung, MD - Stanford University School of Medicine, USA
    "Obstetric complications prior to systemic sclerosis diagnosis"
  • Sue-Ann Ng Pei Lun, MD - Singapore General Hospital, Singapore
    "Evaluating use of T1-MOLLI mapping in assessing systemic sclerosis cardiac involvement"

Awardees of SCTC Travel Awards, 16th International Workshop on Scleroderma Research, Cambridge

Image

Kimberly Showalter:
Histologic Features Correlate with the Modified Rodnan Skin Score, Serum Inflammatory Markers, and Patient Reported Outcomes in Patients with Early, Diffuse Cutaneous Systemic Sclerosis

Andreea Bujor:
Periostin as a novel marker of heart involvement in scleroderma

Silvia Bellando Randone:
The very early diagnosis of systemic sclerosis (VEDOSS) project: predictors to develop definite disease from an international multicentre study

Victoria Flower:
Assessment of the Repeatability and Convergent Validity with Dermal Collagen of High Frequency Ultrasound in Systemic Sclerosis

Emily Mirizio:
Defining the transcriptional profile of the skin in pediatric localized scleroderma (LS)

Pay Membership Fees

If you are a newly accepted member of the SCTC, please select Initial Fee at $250.00 USD.
If you are a returning member of the SCTC, please select the option of Annual Fee at $200.00 USD.
If your institution is unable to use PayPal, please contact admin@sclerodermaclinicaltrials.org.

Membership Fees



© 2020 Scleroderma Clinical Trials Consortium. Designed By Kangablu Ltd